S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Yew Bio-Pharm Group Reports 2013 Fourth Quarter And Full Year Financial Results (2014/3/31)|
|Santarus and Pharming Announce New Data from Open-Label Repeat Treatment Study with RUCONEST (Recombinant Human C1 Esterase Inhibitor) (2013/11/8)|
|Pharming Reports On Financial Results For The First Nine Months Of 2013 ()|
|S&P Capital IQ Initiates Coverage on Yew Bio-Pharm Group in Standard & Poor's Factual Stock Reports ()|
|Pharming announces EU12.0 million private equity placement with institutional investors (2013/10/9)|
|Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ ()|
|PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST (RECOMBINANT HUMAN C1 ESTERASE INHIBITOR) ()|
|PHARMING AND SALIX ANNOUNCE EXTENSION OF PDUFA ACTION DATE FOR RUCONEST(r) (2014/2/24)|
|Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers’ Diarrhea (2013/10/4)|
|Santarus Reports Second Quarter 2013 Financial Results ()|
Click above to view more mutual fund data and stats for pharm - Pharming Group.